START Fortifies Dallas-Fort Worth Oncology Research with New Clinical Director
Event summary
- START appoints Dr. Salwan Al Mutar as Director of Clinical Research at its Dallas-Fort Worth site on April 9, 2026.
- Dr. Al Mutar brings expertise in gastrointestinal oncology and early-phase clinical trials from UT Southwestern.
- Dallas-Fort Worth region sees ~40,000 new cancer cases annually, positioning START for high-volume trial operations.
- Appointment strengthens START's community-based model with academic research experience.
The big picture
START's appointment of Dr. Al Mutar underscores the growing importance of community-based clinical trial sites in accelerating oncology drug development. The move comes as biopharma companies increasingly seek decentralized trial models to improve patient access and enrollment efficiency. With ~40,000 new cancer cases annually in Dallas-Fort Worth, START is positioning itself to capture a significant share of early-phase trial activity in one of the fastest-growing U.S. markets.
What we're watching
- Trial Acceleration
- How Dr. Al Mutar's leadership will impact the pace of early-phase oncology trials in Dallas-Fort Worth.
- Community Integration
- Whether START can sustain its model of integrating complex trials into community settings without compromising quality.
- Regional Expansion
- The pace at which START expands its clinical research footprint in other high-opportunity metropolitan areas.